Funding for this research was provided by:
National Institute on Drug Abuse (UG1DA015815, R01DA037441)
National Center for Advancing Translational Sciences (UL1TR002369)
Received: 26 September 2019
Accepted: 17 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: This project was approved by the OHSU Institutional Review Board and the Vietnam Ministry of Health Research Ethics Committee. Participants provided written consent to participate, which was securely filed. Consents were periodically audited by the study quality assurance monitor for appropriate completion.
: Not applicable.
: No authors have financial conflicts of interest. Dr. Korthuis serves at principal investigator for NIH-funded studies that accept donated study medicine from Indivior (buprenorphine) and Alkermes (extended-release naltrexone).